Expression of p53 and Bcl2 Mammary Adenocarcinoma in C3H Mice Administered With Salvia miltiorrhizae Bunge root extract

*Liza Suryani Dewi  -  Faculty of Medicine Diponegoro University, Indonesia
Noor Widjayahadi  -  Faculty of Medicine Diponegoro University, Indonesia
Indra Wijaya  -  Faculty of Medicine Diponegoro University, Indonesia
Received: 2 Mar 2015; Published: 29 Dec 2016.
Open Access
Citation Format:
Background: Breast cancer is on the first or second most malignancy in many places around the world. The incidence of breast cancer was increasing, also in Indonesia. Prevention and treatment of breast cancer have not been satisfactory, since patients and medical practitioners are searching for other therapeutic and preventive agents. Salvia miltiorrhizae Bunge roots is one of the therapeutics agent used in traditional medicine have been studied in foreign country.
Objective: To prove the p53 and Bcl2 expression in C3H mice mammary adenocarcinoma using multilevel doses of the Salvia miltiorrhizae Bunge roots extract.
Methods :The study is a randomized post-test only controlled group design. A total of 18 adenocarcinoma mice, divided into 3 groups. The first group was administered with 60mg/KgBW/day and the second group was given by 180mg/KgBW/day, for 21 days. All mice were terminated on day 22nd. The p53 and Bcl2 expressions were analyzed using Allred score, statistically analized by Kruskal Wallis followed by Post-Hoc Mann Whitney U test.
Results :Immunohistochemistry staining shows the p53 expressions have been increased between groups, but Bcl2 were decreased. The Kruskal-Wallis and Post-Hoc Mann Whitney U test are significantly difference between groups.
Conclusion :All of the p53 and Bcl2 expressions between groups are significantly differences.

Keywords: mammary adenocarcinoma; Salvia miltiorrhizae Bunge; p53; Bcl2

Article Metrics:

  1. International Agency for Research On Cancer. Latest world cancer statistics global cancer burden rises to 14.1 million new cases in 2012: marked increase in breast cancers must be addressed. [homepage on the Internet]. 2013 [cited 2013 Aug 5]. Available from: United Nation, World Health Organization Web site: http://
  2. Ferlay J, Steliarova-foucher E, Lortet-tieulent J, Rosso S, Coebergh Jww, Comber H, Forman D, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European Journal of Cancer 2013 2012; 49(1):1374-403
  3. Cooper N, Irvine L, Johnson S. What cancer statistics are available, and where can I find them?. (accessed 1 January 2014)
  4. Dhillon PK. Breast cancer factsheet. South Asia Network for Chronic Disease, Public Health Foundation of India. Report number: 03.11.11, 2013
  5. Centers for Disease Control and Prevention. Cancer data and statistics. Atlanta : Centers for Disease Control and Prevention; 2012 (update May 16, 2012; cited Sept 10, 2012). Available from:
  6. National Cancer Insitute. General informaton about breast cancer. Bethesda:USA. Gov;2012 (nodate). Available from :
  7. Blamey RW, Wilson ARM, Patrick J . screening for breast cancer in Dixon J 2nd ed A.B.C of breast disease . BMJ books London, 2000 : 33-7
  8. Traditional Chinese Medicine from Wikipedia, the free encyclopedia.
  9. Wang AM, Sha SH, Lesniak W, Schacht J. Tanshinone (Salviae miltiorrhizae Extract) preparations attenuate aminoglycoside-induced free radical formation in vitro and ototoxicity in vivo. American Society for Microbiology 2003; 47(6):1836-41
  10. Chen J, Chen T. Danshen (radix salvia miltiorrhizae), chapter 12 blood invigorating and stasis removing herbs. Chinese medical herbology and pharmacology. Art of medicine Press., copyright 2004
  11. Song et al. Composition comprising Tanshinone compounds isolated from the extract of Salviae miltiorrhizae radix for treating or preventing cognitive dysfunction and the use thereof. United States Patent Application Publication. Pub No. : US 2009/0312413 A1.Pub.Date : Dec.17, 2009
  12. Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol . 2005;45(12):1345-59
  13. Lu Q, Zhang, Zhang, Chen J. Experimental study o the anti cancer mechanism of tanshinone IIA against human breast cancer. International Journal of molecular medicine 2009; 24:778-80
  14. Nizamutdinova IT, Gyeong WL, Kun HS. Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells. International Journal of Oncology 2008; 33:485-91
  15. Beral V, Banks E, Reeves G, Bull D. Breast cancer and hormone-replacement therapy: the Million Women Study. The Lancet 2003; 362(9392):1330-1
  16. Wang X, Wei Y, Yuan S, Liu G, Lu Y, et al. Potential anticancer activity of tanshinone IIA against human breast cancer, International Journal of Cancer 2005; 116(5):799-807
  17. Su CC, Lin YJ. Tanshinone IIA inhibits human breast cancer cells through increase Bax to Bcl-xL ratios. International journal of molecular 2008; 22(3):357-61
  18. Roomi MZ, Roomi NW, Ivanov V. Research article : Modulaton of N-methyl-N-nitrosourea induced mammary tumors in Sprague-Dawley rats by combination of lysine, proline, arginine, ascorbic acid and green tea extract. Breast Cancer Research [serial on the Internet]. 2005 [cited 2012 Sep 5].;7(3) Available from: Matthias Rath Research, Cancer division Web site: http://
  19. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300
  20. Kumar V, Abbas AK, Aster JC. Robbins Basic Pathology, 9nd ed. Philadelphia: Elsevier Saunders; 2013
  21. Su CC, Chien SY, Kuo SJ, Chen YL, Cheng CY, Chen DR. Tanshinone IIA inhibits human breast cancer MDA-MB-231 Cells by decreasing LC3-II, Erb-B2 and NF-kBp65. Molecular Medicine report 2012; 5(4): 1019-22
  22. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784-92
  23. Jatoi I, Chen BE, Anderson WF, et al. Breast cancer mortality trends in the United States accordin to estrogen receptor status and age at diagnosis. J Clin Oncol 2007;25:1683-90
  24. Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression.J Pathol 2011; 223:307-17
  25. Tavassoli F, A DP.World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the breast and female genital organs.WHO: Geneva, 2003;9-19
  26. Baretta G. Cancer treatment medical guide. 10th ed. Milan (Italy): Farmitalia Carlo Erba-Erbamont; 1991
  27. Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006;208:495-506
  28. Azab S, Al-Hendy A. Signal transduction pathways in breast cancer – drug targets and challenges. In: Gunduz M, Gunduz E. Editors. Breast cancer – carcinogenesis, cell growth, and signaling pathways. Rijeka (Croatia): In Tech; 2011:109-11
  29. Jodi R, Viste, Sherry L, Myers, Singh B, Simko E. Feline mammary adenocarcinoma: tumor size as a prognostic indicator. Can Vet J. 2002; 43(1):33-7
  30. Bland KI, Beenken SW, Copeland III EM. The breast. In: Brunicardi FC, editor. Schwart’z principles of surgery. 8th ed. USA: McGraw-Hill; 2005: 453-91
  31. Conzen SD, Grushko TA, Olopade OI. Cancer of the breast. In: Devita Jr VT, editor. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008:1415-49
  32. Iglehart JD, Smith BL. Diseases of the breast. In: Townsend CM, editor. Sabiston textbook of surgery. 18th ed. Philadelphia : Elsevier-Saunders; 2007
  33. Bland KI, Beenken SW, Copeland III EM. The breast. In: Brunicardi FC, editor. Schwart’z principles of surgery. 8th ed. USA: McGraw-Hill; 2005: 453-91
  34. Rosai J. Rosai and Ackerman’s surgical pathology.10th ed.Philadelphia : Elsevier Inc, 2011
  35. Sausville EA, Longo DL. Principles of cancer treatment. In : Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s principles of internal medicine (book on CD-ROM).15th ed. New York; McGraw-Hill;2001
  36. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P. Anticancer agent targeting signal molecules and cancer cell environtment : challenges for drug development. Journal of the National Cancer Institute 1999 Aug 4;91(15):1281-7
  37. Abbas A, Lichtman AH, Pillai S. Cellular and molecular immunology. 6thed. Philadelphia: Elsevier-Saunders; 2007
  38. Kumar, Abbas, Fausto, Mitchell. Robbins basic pathology 8th ed. Philadelphia: Elsevier Saunders; 2007
  39. Cruse JM, Lewis RE. Atlas of immunology. 2nd ed. Boca Raton, Florida: CRC Press; 2004
  40. The Wikipedia free encyclopedia. Apoptosis. Adelaide: Wikipedia Foundation Inc; 2007. p 1-10. Available from: URL:http//
  41. Brewer DS. Modelling the p53 gene regulatory network (thesis).London:University of London, 2006;297
  42. Vogelstein B, Lane D, Levine A. Surfing the p53 network. Nature, 408(6810):307–10, 2000
  43. Lane DP. Cancer. p53, guardian of the genome. Nature, 358(6381):15–16, Jul 1992
  44. Soussi T, Dehouche K, and Beroud C. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat, 15(1):105–13, 2000
  45. Bode AM and Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer, 4(10):793–805, Oct 2004
  46. Hickman E, Moroni M, and Helin K. The role of p53 and pRB in apoptosis and cancer. Curr Opin Genet Dev, 12(1):60–6, 2002
  47. Harris sl, Levine J. The p53 pathway: positive and negative feedback loops. Oncogene, 24(17):2899–2908, Apr 2005
  48. Clark AR, Gledhill S, Hooper ML, Bird C.C, and Wyllie AH. p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. Oncogene, 9(6):1767–73, Jun 1994
  49. Merritt AJ, Potten CS, Kemp CJ, Hickman JA, Balmain A, Lane DP, and Hall PA. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res, 54(3):614–17, Feb 1994
  50. Wahl G and Carr A. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol, 3(12):E277–86, 2001
  51. Sherr C and Weber J. The ARF/p53 pathway. Curr Opin Genet Dev, 10(1):94–9, 2000
  52. Vousden KH. p53: death star. Cell, 103(5):691–4, Nov 22 2000
  53. Wahl G, Linke S, Paulson T, and Huang L. Maintaining genetic stability through TP53 mediated checkpoint control. Cancer Surv, 29:183–219, 1997
  54. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, and Nakamura Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature, 404(6773):42–9, 2000
  55. Offer H, Zurer I, Banfalvi G, Reha’k M, FalcovitzA, MilyavskyM, Goldfinger N, and Rotter V. p53 modulates base excision repair activity in a cell cycle-specific manner after genotoxic stress. Cancer Res, 61(1):88–96, 2001
  56. Balint E and Vousden K. Activation and activities of the p53 tumour suppressor protein. Br J Cancer, 85(12):1813–23, 2001
  57. Endokrin-related cancer, Society for endocrinology and european society of endocrinology. Available from :
  58. T M Murphy, A S Perry, and M Lawler. Review: The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer Endocr Relat Cancer 2008 15 11-25 (Published 1 March 2008)
  59. Herbal Expert Working Group of the Pan-European Federation of TCM Societies(PEFOT). Danshenform: High quality traditional Chinese herbal medicinal product intended to be registered as a traditional herbal medicinal product in the European Union. Beijing : China Medico-Pharmaceutical Science & Technology Publishing House; 2004
  60. Wang BQ. Salvia miltiorrhiza: chemical and pharmacological review of a medicinal plant. J Med. Plant Res. Vol.4(25); 2813-20
  61. Liu F, Yu G, Wang G, Liu H, Wu X,wang Q, et al. An NQO1-Initiated and p53-independent apoptotic pathway determines the anti-tumor effect of tanshinone IIA against non-small cell lung cancer. Plos ONE Jurnal.Pone 2012; 7(7):e42138
  62. Gay WI. Methods of animal experimentation. 1th ed. New York ; Academic Pres Inc, 1965
  63. Perhimpunan Dokter Spesialis Patologi Indonesia(IAPI). Pedomen penanganan bahan pemeriksaan untuk histopatologi. 1th ed. Jakarta, 2008
  64. Prophet E, Mills B, Arrington JB, Sobin LH. Laboratory methods in histotechnology. 1th ed. Washington DC : American Registry of Pathologu, 1994
  65. Lee CY, Sher HF, Chen HW, et al. Anticancer effects of tanshinone I in human non-small cell lung cancer. Mol Cancer Ther 2008;7:3527-3538. Published online November 11, 2008. Access the most recent version of this article at: doi: 10.1158/1535-7163.MCT-07-2288.Accessthemostrecentsupplementalmaterialat:,2012.Copyright©2008AmericanAssociationforCancerResearch
  66. Qureshi A, Pervez S. Allred scoring for ER reporting and it's impact in clearly distinguishing ER negative from ER positive breast cancers. J Pak Med Assoc 2010; 60(5):350-3
  67. Jensen MM, Jorgensen JT, Binderup T, Kjaer A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by F-FDG-microPET or external caliper. BMC Medical Imaging, 2008 ;8(16): 1-9

Last update: 2021-04-20 11:57:23

No citation recorded.

Last update: 2021-04-20 11:57:24

No citation recorded.